Trending...
- Nexamp Earns Recognition from U.S. Department of Labor as Registered Apprenticeship Program Employer - 513
- 'Heads Up Boston' Campaign to Destigmatize Youth Mental Health
- City of Boston Receives $9.8 Million to Build a Climate-Ready Workforce
BOSTON ~ Tectonic Therapeutic, Inc., a biotechnology company specializing in the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), has announced the completion of dosing of the first human cohort in its Fc-relaxin fusion program targeting the RXFP1 receptor.
Alise Reicin, MD, President and Chief Executive Officer of Tectonic Therapeutic, expressed her excitement at this milestone: "The start of our first-in-human study is a critical and exciting milestone. We look forward to seeing the potential of relaxin biology realized in patients."
Relaxin is known as a "pregnancy hormone" and is upregulated during pregnancy to help the expectant mother's cardiovascular system meet the increased demand from the developing fetus, and to remodel tissues and musculoskeletal structures involved in childbirth. It also produces a unique and diverse range of biological effects that include pulmonary and systemic vasodilation, tissue remodeling / fibrosis reversal and reduction of inflammation. This makes it a potential therapeutic agent for cardio-pulmonary diseases.
More on Boston Chron
Tectonic's TX000045 Fc-relaxin fusion protein ("TX45") is an engineered protein designed to overcome biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose escalation safety studies in healthy volunteers, continued development will focus on addressing areas of very high unmet need in cardio-pulmonary indications.
Tim Springer, PhD, Co-Founder of Tectonic and Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston commented: "TX45 could be a potentially transformative therapy for a vast number of patients with cardiovascular diseases... TX45 is exemplary of the company's ability to execute in the development of novel GPCR-targeted biologics. We look forward to future clinical programs emerging from Tectonic's platform."
Tectonic Therapeutic's announcement marks an important milestone in their efforts to develop novel GPCR-targeted therapies for cardio-pulmonary diseases using relaxin as an agonist for RXFP1 receptor activation. With their engineered protein TX45 offering potential best-in-class properties, they are hopeful that it will be able to address areas with very high unmet need in these indications.
Alise Reicin, MD, President and Chief Executive Officer of Tectonic Therapeutic, expressed her excitement at this milestone: "The start of our first-in-human study is a critical and exciting milestone. We look forward to seeing the potential of relaxin biology realized in patients."
Relaxin is known as a "pregnancy hormone" and is upregulated during pregnancy to help the expectant mother's cardiovascular system meet the increased demand from the developing fetus, and to remodel tissues and musculoskeletal structures involved in childbirth. It also produces a unique and diverse range of biological effects that include pulmonary and systemic vasodilation, tissue remodeling / fibrosis reversal and reduction of inflammation. This makes it a potential therapeutic agent for cardio-pulmonary diseases.
More on Boston Chron
- Liberty Mutual Insurance Appoints Nicole Arangio to Executive Vice President and Chief Compliance Officer
- 418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
- Rising Stars Romulus First Debuts Genre-Bending Album "Reality"
- Boston: Council Reaffirms the Trust Act
- Boston: The Healthy Incentives Program
Tectonic's TX000045 Fc-relaxin fusion protein ("TX45") is an engineered protein designed to overcome biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose escalation safety studies in healthy volunteers, continued development will focus on addressing areas of very high unmet need in cardio-pulmonary indications.
Tim Springer, PhD, Co-Founder of Tectonic and Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston commented: "TX45 could be a potentially transformative therapy for a vast number of patients with cardiovascular diseases... TX45 is exemplary of the company's ability to execute in the development of novel GPCR-targeted biologics. We look forward to future clinical programs emerging from Tectonic's platform."
Tectonic Therapeutic's announcement marks an important milestone in their efforts to develop novel GPCR-targeted therapies for cardio-pulmonary diseases using relaxin as an agonist for RXFP1 receptor activation. With their engineered protein TX45 offering potential best-in-class properties, they are hopeful that it will be able to address areas with very high unmet need in these indications.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston: La Alianza Hispana
- Boston Medical Center's Living Well at Home Program
- Youth Group Makes History as First Visitors to National Electronics Museum
- Boston: The Irish Pastoral Centre - "Here Together"
- Peter C.Marcucci and Lovelie Avril Married in Boston
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
- Shape the Future of OpenSSL: Election Period Open Now!
- LIB Empowers Uzbekistan's Automotive Industry: A New Era of Quality Assurance
- TijaraIQ.com Launches as Iraq's Free Marketplace for Buying, Selling, and Creating Opportunities
- Big News!! Best Sac Homes Group Partners with LPT Realty
- Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
- Dale Sorensen Real Estate Names Donna Browning Vice President of Sales, Announcing Her Return to the Company
- Dr. Barrie Matthews of Big Sky Smile Center Speaks at the Full Arch Growth Conference, Inspiring Dentists Nationwide
- Boston: Mayor Michelle Wu and Office of Black Male Advancement Launch Third Annual Community Empowerment Grants
- Dr. Sathish Palayam Speaks at the Full Arch Growth Conference, Sharing Insights to Revolutionize Patient Care!
- Donors and Recipients of Nashville Chopin's Metro School Piano Donation Program Announced
- Loyal American Airlines Passenger and Son of 33-Year Employee Files Legal Action Against Airline for Racial Bias, Unlawful Ban, and Injustice
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Mayor Wu Announces Boston Family Days, Offering Free Access for Families at Nine Institutions Across Boston
- Pittsburgh Professional Women invites all Women and Allies to MONEY CLUB